Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early aspirin use leads to 14% lower mortality, fewer recurrent ischemic strokes -- study.

This article was originally published in The Tan Sheet

Executive Summary

EARLY ASPIRIN USE LEADS TO 14% LOWER MORTALITY, FEWER RECURRENT ISCHEMIC STROKES, but more hemorrhagic strokes among stroke patients participating in the Chinese Acute Stroke Trial (CAST). The study included 21,106 patients with acute ischemic stroke admitted into 413 Chinese hospitals. The large, randomized, placebo-controlled trial measured the effects of aspirin treatment (160 mg/day) begun within 48 hours of the onset of suspected acute ischemic stroke and continued in the hospital for up to four weeks. The primary endpoints were death during the treatment period and death or physical dependence at discharge. CAST was published in the June 7 issue The Lancet.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel